CanSino Biologics Management
Management criteria checks 4/4
CanSino Biologics' CEO is Xuefeng Yu, appointed in Jan 2009, has a tenure of 15.92 years. total yearly compensation is CN¥3.97M, comprised of 64.1% salary and 35.9% bonuses, including company stock and options. directly owns 7.28% of the company’s shares, worth €101.24M. The average tenure of the management team and the board of directors is 6.8 years and 3.2 years respectively.
Key information
Xuefeng Yu
Chief executive officer
CN¥4.0m
Total compensation
| CEO salary percentage | 64.1% |
| CEO tenure | 15.9yrs |
| CEO ownership | 7.3% |
| Management average tenure | 6.8yrs |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -CN¥720m |
| Jun 30 2024 | n/a | n/a | -CN¥867m |
| Mar 31 2024 | n/a | n/a | -CN¥2b |
| Dec 31 2023 | CN¥4m | CN¥3m | -CN¥1b |
| Sep 30 2023 | n/a | n/a | -CN¥1b |
| Jun 30 2023 | n/a | n/a | -CN¥2b |
| Mar 31 2023 | n/a | n/a | -CN¥1b |
| Dec 31 2022 | CN¥5m | CN¥2m | -CN¥909m |
Compensation vs Market: Xuefeng's total compensation ($USD543.29K) is below average for companies of similar size in the German market ($USD1.51M).
Compensation vs Earnings: Xuefeng's compensation has been consistent with company performance over the past year.
CEO
Xuefeng Yu (59 yo)
15.9yrs
Tenure
CN¥3,965,000
Compensation
Dr. Xuefeng Yu, Ph D, is Co-Founder of CanSino Biologics Inc. since 2009. Dr. Yu serves as an Executive Director at CanSino Biologics Inc. since January 13, 2009 and has served as its Chief Executive Offic...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.9yrs | CN¥3.97m | 7.28% € 101.2m | |
| Co-Founder | 15.9yrs | CN¥4.42m | 7.27% € 101.2m | |
| Co-Founder | 15.9yrs | CN¥3.74m | 6.94% € 96.5m | |
| COO, Deputy GM & Executive Director | 6.6yrs | CN¥3.93m | 0.028% € 383.1k | |
| Chief Commercial Officer | 3.3yrs | CN¥4.57m | 0.0072% € 100.3k | |
| Senior Director of New Technology Department | 7.1yrs | no data | no data | |
| Vice President of Marketing | no data | no data | no data | |
| Board Secretary | 5.8yrs | no data | no data | |
| Joint Company Secretary | 5.8yrs | no data | no data |
6.8yrs
Average Tenure
51yo
Average Age
Experienced Management: CJH's management team is seasoned and experienced (6.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.9yrs | CN¥3.97m | 7.28% € 101.2m | |
| COO, Deputy GM & Executive Director | 6.5yrs | CN¥3.93m | 0.028% € 383.1k | |
| Chief Commercial Officer | 3.2yrs | CN¥4.57m | 0.0072% € 100.3k | |
| Co-Chair of Scientific Advisory Board | 1.9yrs | no data | no data | |
| Member of the Scientific Advisory Board | 2.6yrs | no data | no data | |
| Independent Non-Executive Director | 5.1yrs | CN¥300.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Employee Representative Supervisor | less than a year | no data | no data | |
| Independent Non-Executive Director | 5.1yrs | CN¥300.00k | 0.00040% € 5.6k | |
| Co-Chair of Scientific Advisory Board | 1.9yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | no data | no data | no data |
3.2yrs
Average Tenure
59yo
Average Age
Experienced Board: CJH's board of directors are considered experienced (3.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 16:03 |
| End of Day Share Price | 2024/12/12 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CanSino Biologics Inc. is covered by 19 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Lijian Zhao | China International Capital Corporation Limited |
| Hangci Zheng | China International Capital Corporation Limited |